HBM Healthcare Investments Achieves Notable NAV Growth in Q2

HBM Healthcare Investments AG reported significant financial performance in the second quarter of the 2025/2026 fiscal year. The company saw a 16.4% increase in net asset value (NAV) per share, reaching CHF 251.78. This resulted in a quarterly profit of CHF 236 million, successfully counterbalancing the prior quarter's currency-related loss.

Over the first half of the fiscal year, HBM anticipates a profit of CHF 96 million with NAV growth of 6.1% in Swiss francs, equal to 17.8% in US dollars. Despite a 4.0% increase in share price during this period, the shares continue to trade at a 28% discount to NAV.

The positive second-quarter performance was driven by gains in the listed portfolio, spurred by successful clinical trials and takeover bids involving key companies such as Abivax and Merus. The outlook remains optimistic for continued growth in both private and listed investments.